Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · West Pharmaceutical Services (WST)

West Pharmaceutical: Chief Commercial Officer Cindy Reiss-Clark departs, severance agreed

Neutral Impact 2 of 5 leadership Written later

West Pharmaceutical Services disclosed that Cindy Reiss-Clark, its former Senior Vice President and Chief Commercial Officer and a named executive officer, left the company effective March 7, 2025. She signed a Separation Agreement and Release dated April 9, 2025, which provides one year of salary continuation and other benefits in exchange for a release of claims and continued restrictive covenants.

Key points

  • Departure effective March 7, 2025; role was Senior Vice President and Chief Commercial Officer
  • Salary continuation for one year at a salary of $489,500, plus continued welfare benefits
  • 2025 payment of $57,526 for pro-rated Annual Incentive Plan target; outplacement services up to $15,000

The filing

CompanyWest Pharmaceutical Services (WST)
Form8-K, current report
Filed with the SECApr 14, 2025, 4:09 PM ET
Accession number0000105770-25-000022

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 14, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.